Bone Biologics
BBLG
6 hedge funds and large institutions have $576K invested in Bone Biologics in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 3 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
0.26% more ownership
Funds ownership: 0.01% → 0.27% (+0.26%)
11% less capital invested
Capital invested by funds: $647K → $576K (-$70.9K)
14% less funds holding
Funds holding: 7 → 6 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Walleye Capital
New York
|
+$1.46M |
| 2 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
+$142K |
| 3 |
VF
Virtu Financial
New York
|
+$86.9K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$31.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$214K |
| 2 |
MWA
MFA Wealth Advisors
Pittsburgh,
Pennsylvania
|
-$25K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$11.3K |
| 4 |
Millennium Management
New York
|
-$5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Walleye Capital
New York
| $419K | +$1.46M | +5,586 | +998% |
|
|
KC
2
Kepos Capital
New York
| $72K | +$273K | +1,042 | New |
|
|
WAM
3
Warberg Asset Management
Winnetka,
Illinois
| $38.3K | +$142K | +542 | +2,581% |
|
|
VF
4
Virtu Financial
New York
| $23K | +$86.9K | +332 | New |
|
|
SM
5
Sabby Management
Miami Beach,
Florida
| $15.5K | -$214K | -817 | -78% |
|
|
TRCT
6
Tower Research Capital (TRC)
New York
| $8.64K | +$31.4K | +120 | +2,000% |
|
7
Wells Fargo
San Francisco,
California
| $3 | – | – | – |
|
|
MWA
8
MFA Wealth Advisors
Pittsburgh,
Pennsylvania
| – | -$25K | -67 | Closed |
|
|
9
UBS Group
Zurich,
Switzerland
| – | -$11.3K | -30 | Closed |
|
|
10
Millennium Management
New York
| – | -$5K | -12 | Closed |
|
BBLG Hedge Fund Activity: Q2 2023 in Review
6 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Bone Biologics (BBLG) for Q2 2023, worth a combined $576K — down 11% from $647K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of BBLG and 2 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 3 added.
The largest buyer was Walleye Capital, adding an estimated $1.46M. The largest seller was Sabby Management, cutting an estimated $214K.
- 6 institutional investors held Bone Biologics (BBLG) as of Q2 2023, down from 7 in Q1 2023.
- Funds reported $576K of Bone Biologics stock for Q2 2023, down 11% quarter-over-quarter.
- 2 funds opened new Bone Biologics positions in Q2 2023 and 3 closed out, a net change of -1 holder.
- The largest Bone Biologics buyer in Q2 2023 was Walleye Capital, an estimated $1.46M added.
- The largest Bone Biologics seller in Q2 2023 was Sabby Management, an estimated $214K sold.
Based on aggregated 13F filings for Q2 2023.